*n this talk, I will present an overview of Immunai, its immune profiling platform, leveraging multi-modal profiling of immune cells with a single-cell resolution taken from blood and solid tissues in order to create patients' longitudinal immune profiles and measure changes post-therapy. This information is harmonized into AMICA, the largest clinical-omics immune database, from which actionable insights are derived using proprietary ML/AI models. We will present case studies from recent collaborations with pharma companies that showcase the platform's capabilities.*